Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Duloxetine: urinary incontinence and marketing authorization incontinence

Alain Braillon
CMAJ March 06, 2017 189 (9) E373; DOI: https://doi.org/10.1503/cmaj.732561
Alain Braillon
Senior consultant, University Hospital, Amiens, France
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Maund and colleagues1 rightly questioned the use of duloxetine for stress urinary incontinence, with a focus on harms related to suicidality and violent behaviour, but the problem is deeper.

First, duloxetine has no advantages versus other antidepressants, but has only specific serious adverse effects, such as life-threatening liver injury2 and severe skin reactions, including Stevens–Johnson syndrome. 3 Duloxetine is in a yearly list of “drugs to avoid” — drugs on the market that are more harmful than beneficial.4 This Choosing Wisely initiative remains deliberately ignored by regulatory agencies.

Second, patients with stress incontinence are usually older, and as a result coexistence of other somatic diseases is very frequent with polymedication. This is a major drug safety issue.

Last, how could the European Medicine Agency have granted a marketing authorization for stress urinary incontinence without either long-term assessment of the safety or adequate assessment of efficacy versus a comparator? Indeed, other options, with a stepped-care approach that advances from least invasive to more invasive interventions, are available (e.g., behavioural modification, pelvic floor muscle exercises, noninvasive stimulation, vaginal inserts, urethral plugs, neuromodulation devices, injections of periurethral bulking agents, and sling and urethropexy procedures).5 No medications are approved by the United States Food and Drug Administration for this condition. Why this European exception? Exceptions rarely benefit patients.

Why do some practitioners prescribe duloxetine, whatever the indication, and ignore safer alternatives?

Footnotes

  • Competing interests: None declared.

References

  1. ↵
    1. Maund E,
    2. Guski LS,
    3. Gøtzsche PC
    . Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ 2017; 189: E194–203.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Wernicke J,
    2. Pangallo B,
    3. Wang F,
    4. et al
    . Hepatic effects of duloxetine-I: non-clinical and clinical trial data [published erratum in Curr Drug Saf 2009; 4:94]. Curr Drug Saf 2008;3:132–42.
    OpenUrlCrossRefPubMed
  3. ↵
    Cymbalta (duloxetine hydrochloride). Silver Spring (MD): US Food and Drug Administration; 2011. Available: www.fda.gov/Safety/MedWatch/SafetyInformation/ucm255064.htm (accessed 2017 Jan. 27)
  4. ↵
    Towards better patient care: drugs to avoid in 2016 [article in French]. Prescrire Int 2016;25: 105–11.
    OpenUrl
  5. ↵
    1. Hersh L,
    2. Salzman B
    . Clinical management of urinary incontinence in women [published erratum in Am Fam Physician 2013;88:427]. Am Fam Physician 2013;87:634–40.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (9)
CMAJ
Vol. 189, Issue 9
6 Mar 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Duloxetine: urinary incontinence and marketing authorization incontinence
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Duloxetine: urinary incontinence and marketing authorization incontinence
Alain Braillon
CMAJ Mar 2017, 189 (9) E373; DOI: 10.1503/cmaj.732561

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Duloxetine: urinary incontinence and marketing authorization incontinence
Alain Braillon
CMAJ Mar 2017, 189 (9) E373; DOI: 10.1503/cmaj.732561
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire